AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 112 min read$CC

Martinko Joseph T. purchased $30K of CC

Martinko Joseph T. (See Remarks) purchased 1,940 shares of Chemours Co (CC) at $15.47 on 2026-08-07.

Original reporting
SEC EDGAR · Martinko Joseph T.
Published Aug 11, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CC
Neutral
low confidence
Mentioned
$CC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCNeutralLow
01

Why it matters

The newest fact is the disclosed open-market purchase amount, price, and post-transaction holdings; it does not include any operational or financial update.

02

Market read

Traders may note the insider buy as a minor sentiment input, but there is no fundamental catalyst in the text.

03

What to watch

The article does not state the insider’s broader trading history, intent, or whether the purchase was part of a larger pattern, limiting signal quality.

Relevance 4/10Novelty 3/10Timing: Form 4 filed 2026-08-11, transaction dated 2026-08-07.

Background

The article is a SEC Form 4 insider transaction disclosure for Chemours (CC) by officer Martinko Joseph T.

Company-level read

Ticker impact

$CCNeutralLow confidence
Context

Chemours (CC) disclosed an officer open-market purchase of 1,940 shares at $15.4700 on 2026-08-07 via Form 4 filed 2026-08-11.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a routine Form 4 insider transaction with modest size ($30,008.73) and no accompanying guidance, contract, or operational change.

Market effects

Sector

No clear sector read-through; this is company-specific insider activity without new sector data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine liquidity or diversification actions and may not reflect a strong forward view, especially without a 10b5-1 plan.

Key entities

  • issuer
    Chemours Co

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Martinko Joseph T.

    Officer who purchased 1,940 shares of CC at $15.4700 on 2026-08-07.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CC insider trading history →

Related articles

AUG 8
$CCMed

Why Chemours Plunged on Wednesday

Chemours (NYSE: CC) shares fell 18.7% after its Q2 earnings. The company reported slight revenue decline and adjusted EPS of $0.42, down 31% year over year, meeting expectations. Management cited lower Optane refrigerant sales due to supply-chain inventory and the wind-down of the SPS Capstone business. Full-year growth guidance remains 1% to 5%.

aol.com6 min
AUG 5
$CCMed

Why Chemours Plunged on Wednesday

Chemours (NYSE: CC) shares fell 18.7% after the company reported Q2 results. Revenue edged down and adjusted EPS fell 31% to $0.42, missing expectations. Lower Optane refrigerant sales and the prior wind-down of the SPS Capstone business weighed on results. Chemours still forecasts full-year growth of 1% to 5%.

yahoo.com4 min
AUG 4
$CCMedAI 8/10

The Chemours Company Reports Second Quarter Results

Chemours (NYSE: CC) reported Q2 2026 results: net sales about $1.6B, roughly flat year over year. Net loss attributable to Chemours was $274M ($1.81 per diluted share) versus $380M ($2.53) a year earlier. Adjusted net income was $64M ($0.42) and adjusted EBITDA $247M. Free cash flow rose 128% and net leverage fell to 4.4x. Chemours cited TiO2 pricing actions and APM Performance Solutions growth.

prnewswire.com7 min
AUG 4
$CCMed

Chemours Co (CC): Results of Operations and Financial Condition

Chemours Co (CC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cc-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 The Chemours Company Reports Second Quarter Results Wilmington, Del., August 4, 2026 – The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Special

SEC EDGAR 8-K6 min
JUL 9
$MMMHighAI 9/10

New York sues 3M, DuPont and other chemical companies over PFAS pollution By Investing.com

New York Attorney General Letitia James sued 3M, DuPont, Chemours, Corteva and EIDP over alleged PFAS (“forever chemicals”) contamination. The complaint says the firms knew since decades-old research that PFAS were toxic but concealed risks, continued selling PFAS products, and allegedly misled consumers. New York seeks cleanup funding, consumer warnings, advertising changes, and damages and penalties.

investing.com3 min